Physician profile
John W Branch
NPI 1417142977
$4,738.63
in general payments reported to CMS, 2019-2025
12 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 81% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $256 · 2021: $712 · 2022: $452 · 2023: $734 · 2024: $497 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,422 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,421.80 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,469.74 | 2019-2025 | Centurion, Wavelight Refractive Suite, Contoura Vision |
| Johnson & Johnson Surgical Vision, INC. | $1,421.91 | 2019-2025 | Veritas Vision System, Tecnis Iol, Tecnis Simplicity |
| Rxsight INC | $1,049.82 | 2021-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Biotissue Holdings INC. | $304.63 | 2022-2025 | |
| Carl Zeiss Meditec, INC. | $137.19 | 2023 | Artevo 800, Lumera 700 |
| Mallinckrodt Enterprises LLC | $119.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $94.70 | 2019 | |
| Harrow Eye, LLC | $42.16 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $36.94 | 2023-2025 | Envista Envy Iol, Envista Mx60 Iol |
| Ivantis, INC | $33.00 | 2021 | |
| Vantage Technology LLC | $16.00 | 2019 | |
| Visioneering Technologies, INC. | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Branch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.